90 Results for "

Treg

" in MedChemExpress (MCE) Product Catalog:
Products (90)

90 Results for "Treg" in MCE Product Catalog:

Cat. No.: HY-P4790
CAS No.: 305815-28-5
Target:  

PI3K Akt

Research Areas:  

Metabolic Disease

Acetyl-Exenatideyes is an acetylated derivative of Exenatide. Exenatide has the function similar to insulin, which can be used for research of type 2 diabetes. Exenatide can promote Th17 differentiation, inhibits Tregs differentiation, downregulates PI3K/Akt/FoxO1 phosphorylation .
loading...
    loading...
Cat. No.: HY-B0172AS1
CAS No.: 2410277-60-8
Synonyms: 3β-Hydroxy-5α-cholanic acid-d4
Isoallolithocholic acid-d4 (3β-Hydroxy-5α-cholanic acid-d4) is deuterium labeled Isoallolithocholic acid. Isoallolithocholic acid (3β-Hydroxy-5α-cholanic acid), a derivative of Lithocholic acid (HY-10219), is a T cell regulator. Isoallolithocholic acid enhances regulatory T cells (Tregs) differentiation .
loading...
    loading...
Cat. No.: HY-120785A
CAS No.: 2309312-90-9
Target:  

ROR

Research Areas:  

Inflammation/Immunology

SR1555 hydrochloride is the hydrochloride salt form of SR1555 (HY-120785). SR1555 hydrochloride is an inverse agonist for retinoic acid receptor-related orphan nuclear receptor γ (RORγ) with an IC50 of 1 μM. SR1555 hydrochloride inhibits the development and function of pro-inflammatory TH17 cell, increases the frequency of anti-inflammatory T regulatory (Treg) cells. SR1555 hydrochloride can be used for research about autoimmune diseases .
loading...
    loading...
Cat. No.: HY-W713010
3-Epideoxycholic acid-d5 is the deuterium labeled 3-Epideoxycholic acid (HY-48814). 3-Epideoxycholic acid is the microbial metabolite of Deoxycholic acid (HY-N0593). 3-Epideoxycholic acid targets FXR of dendritic cells, reduces their immunostimulatory properties, promotes the generation of Treg cells, and exhibits anti-inflammatory activity. 3-Epideoxycholic acid promotes the growth of bacteria Bacteroides .
loading...
    loading...
Cat. No.: HY-P10982
CAS No.: 2767993-73-5
Research Areas:  

Inflammation/Immunology

SjDX5-53 is a selective TLR2 inducer derived from a 3 kDa peptide from Schistosoma japonicum eggs. SjDX5-53 inhibits inflammatory Th1 and Th17 responses by inducing tolerogenic dendritic cells (tolDCs) and promoting the generation of regulatory T cells (Tregs) and their suppressive capacity. SjDX5-53 is primarily used in the treatment of autoimmune and inflammatory diseases such as colitis and psoriasis .
loading...
    loading...
Cat. No.: HY-P990177

Target:  

Notch Influenza Virus

Research Areas:  

Infection Inflammation/Immunology

Anti-Mouse Notch4 Antibody (HMN4-14) is an anti-mouse Notch4 IgG monoclonal antibody. Anti-Mouse Notch4 Antibody (HMN4-14) reduces inflammation by restoring the expression of bispecific proteins. Anti-Mouse Notch4 Antibody (HMN4-14) can inhibit Th2/Th17 cell differentiation and improve Treg cell function. Anti-Mouse Notch4 Antibody (HMN4-14) can be used for research on inflammation conditions such as viral pneumonia and airway inflammation .
loading...
    loading...
Cat. No.: HY-P990206

Research Areas:  

Inflammation/Immunology

Anti-Mouse Jagged 2 Antibody (HMJ2-1) is an anti-mouse Jagged 2 IgG monoclonal antibody. Anti-Mouse Jagged 2 Antibody (HMJ2-1) regulates Treg/Th17 balance through IL-9. Anti-Mouse Jagged 2 Antibody (HMJ2-1) increases Jagged2-Notch signaling through activation of RBP-Jk. Anti-Mouse Jagged 2 Antibody (HMJ2-1) can be used for researches on inflammation conditions and xenotransplantation such as experimental autoimmune encephalomyelitis (EAE) .
loading...
    loading...
Cat. No.: HY-B1346R
CAS No.: 6899-04-3
Synonyms: (±)-Glutamine (Standard); DL-Gl (Standard)
DL-Glutamine (Standard) ((±)-Glutamine (Standard); DL-Gl (Standard)) is the analytical standard of DL-Glutamine (HY-B1346). This product is intended for research and analytical applications. DL-Glutamine ((±)-Glutamine; DL-Gl) is an amino acid metabolite. DL-Glutamine is a plasma metabolic biomarker associated with Treg/Th17 balance in an OVA-induced eosinophilic asthma mouse model. DL-glutamine positively correlates with muscle quality parameters such as muscle water-holding capacity and shear force, and negatively correlates with oxidative stress markers and apoptotic gene expression. DL-Glutamine is associated with periodontal pathogens and oral microbial communities in saliva/serum. DL-Glutamine can be used in research related to asthma, muscle quality, and periodontal disease .
loading...
    loading...
Cat. No.: HY-W016773S
CAS No.: 347841-78-5
1,10-Decanediol-d20 is the deuterium labeled 1,10-Decanediol . 1,10-Decanediol is a diol compound that can react with α-ketoglutarate (aKG) to generate polymeric microparticles (termed paKG MPs) for the sustained release of aKG, thereby promoting immunosuppressive regulation. Additionally, paKG MPs can bind to dendritic cells (DCs), reducing their glycolysis and mitochondrial respiration in vitro. These metabolic changes lead to the modulation of MHC-II and CD86 expression in DCs and alter the frequency of regulatory T cells (Tregs) as well as T-helper type 1/2/17 cells in vitro. 1,10-Decanediol can be used in research within the field of immunometabolism. can be used as a surfactant/stabilizer in the synthesis of nanomaterials .
loading...
    loading...
Cat. No.: HY-162415
CAS No.: 2760585-35-9
Target:  

c-Fms Apoptosis

Research Areas:  

Cancer

CSF1R-IN-22 (Compound C19) is an orally effective CSF-1R selective inhibitor (IC50<6 nM). CSF1R-IN-22 enhances the secretion of CXCL9 from M2 macrophages, increases CD8 + T cell infiltration. CSF1R-IN-22 boosts anti-tumor immune responses of anti-PD-1, and induces apoptosis in tumor cells. CSF1R-IN-22 can effectively reprogram M2-like TAMs (tumor-associated macrophages) to the M1 phenotype and reshape the TME by inducing the recruitment of CD8 + T cells into tumors and reducing the infiltration of immunosuppressive Tregs and MDSCs .
loading...
    loading...
Cat. No.: HY-P99911
CAS No.: 1635395-27-5
Synonyms: MEDI-6383
Efizonerimod alfa (MEDI-6383) is a recombinant human OX40L IgG4P Fc fusion protein that assembles into a hexameric structure and exerts potent agonist activity upon binding to OX40. The activity of Efizonerimod alfa is enhanced by Fcγ receptor-mediated aggregation. Efizonerimod alfa binds to OX40 on the surface of activated T cells, induces NF-κB promoter activity in OX40-expressing T cells, and triggers the production of Th1-type cytokines, T cell proliferation, and resistance to regulatory T cell (Treg)-mediated suppression. Efizonerimod alfa enhances the cytolytic activity of tumor-reactive T cells and slows tumor growth in immunodeficient mice. Efizonerimod alfa induces the proliferation of CD4, CD8, and B cells in the peripheral blood of healthy non-human primates. Efizonerimod alfa can be used in the research of advanced solid malignancies and melanoma .
loading...
    loading...
Cat. No.: HY-P991944

Target:  

CCR

Research Areas:  

Cancer

ZL-1218 is a selective humanized IgG1 antibody, targeting CCR8. ZL-1218 induces antibody-dependent cellular cytotoxicity (ADCC), leading to NK cell-mediated depletion of CCR8-expressing regulatory T cells (Tregs). ZL-1218 blocks the binding of the CCR8 ligand CCL1 to CCR8 and reduces Treg recruitment by inhibiting the chemotaxis of CCR8 + cells. ZL-1218 reduces intratumoral Treg levels in a dose-dependent manner. ZL-1218 exerts enhanced antitumor activity when combined with the anti-PD-1 antibody. ZL-1218 can be used for solid tumour research .
loading...
    loading...
Cat. No.: HY-N17465
CAS No.: 526222-27-5
Dendronobiloside D is a sesquiterpene glycoside that can be isolated from Dendrobium officinale. Dendronobiloside D is an immunosuppressant that promotes the differentiation of CD4 + T cells into Treg cells .
loading...
    loading...
Cat. No.: HY-P991942A
Synonyms: BAY3375968 (FUT8-KO); TPP-23411 (FUT8-KO)
Target:  

CCR

Research Areas:  

Cancer

Lanerkitug (FUT8-KO) (BAY3375968 (FUT8-KO)) is an anti-CCR8 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Lanerkitug (HY-P991942) selectively depletes human CCR8+Tregs via antibody dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP). Lanerkitug can be used in the research of solid tumors .
loading...
    loading...
Cat. No.: HY-P11014
Research Areas:  

Inflammation/Immunology

SjDX5-53 control peptide is a control peptide of the TLR2 activator SjDX5-53 (HY-P10982) that does not target a specific receptor and does not modulate regulatory T cells (Tregs) or dendritic cells. SjDX5-53 control peptide can be used to exclude nonspecific effects and help verify the specific role of SjDX5-53 in inducing Tregs and alleviating autoimmune diseases. SjDX5-53 control peptide is used in the study of autoimmune diseases such as colitis and psoriasis .
loading...
    loading...
Cat. No.: HY-P992029

Target:  

Interleukin Related

Research Areas:  

Inflammation/Immunology Cancer

RTX-003 is a monoclonal antibody targeting CD25. RTX-003 induces the death of regulatory T cells (Tregs) by targeting the IL-2 receptor α chain (CD25), and can enhance anti-tumor immune responses.
loading...
    loading...
Cat. No.: HY-P992361

Research Areas:  

Cancer

HB0030 is a TIGIT inhibitor with antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) activities. HB0030 enhances the expression of activation markers in natural killer (NK) cells, promotes the killing of regulatory T cells (Tregs), and reduces the proportion of FoxP3 + Treg in tumor-infiltrating lymphocytes. The combination of HB0030 with the anti-PD-L1/VEGF bispecific antibody HB0025 further enhances tumor suppression efficacy. HB0030 can be used in studies related to colorectal cancer, pancreatic adenocarcinoma, hepatocellular carcinoma, bladder cancer, breast cancer, non-small cell lung cancer, and advanced solid tumors .
loading...
    loading...
Cat. No.: HY-P992365

Target:  

CCR

Research Areas:  

Cancer

HFB101110 is a human-derived inhibitor and Treg depleter that specifically targets CCR8. It does not bind to the homologous CCR4 receptor and is mainly used in research on solid tumors, renal cell carcinoma and colorectal cancer. HFB101110 blocks hCCL1 binding by interacting with the N-terminal extracellular domain of hCCR8, thereby inhibiting hCCL1-induced calcium influx, chemotaxis and downstream signaling pathways. Meanwhile, HFB101110 can mediate ADCC effects to specifically deplete CCR8-positive cells, including intratumoral Tregs. HFB101110 exhibits favorable anti-tumor activity and pharmacokinetic properties .
loading...
    loading...
Cat. No.: HY-P991942
Synonyms: BAY3375968; TPP-23411

Target:  

CCR

Research Areas:  

Inflammation/Immunology Cancer

Lanerkitug (BAY3375968) is a fully human monoclonal IgG1 anti-human CCR8 antibody. Lanerkitug selectively depletes human CCR8 + Tregs via antibody dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP). Lanerkitug can be used in the research of solid tumors .
loading...
    loading...
Cat. No.: HY-P991911

Research Areas:  

Cancer

PLT012 is a humanized IgG4 antibody targeting CD36. PLT012 inhibits the lipid-binding domain of CD36. PLT012 blocks CD36-mediated metabolic adaptation in regulatory T cells (Tregs) and CD8 + tumor-infiltrating lymphocytes (TILs), thereby inhibiting tumor growth and shifting the tumor microenvironment from immunosuppressive to immunosupportive. PLT012 reduces intratumoral Tregs, enhances CD8 + T cell infiltration and cytotoxic function, and increases the abundance of progenitor-exhausted T cells. PLT012 exerts robust antitumor activity and synergizes with anti-PD-L1 or standard-of-care regimens (anti-VEGF + anti-PD-L1). PLT012 can be used for hepatocellular carcinoma, colorectal cancer and solid tumor research .
loading...
    loading...